Spurious HbA1c results in patients with diabetes treated with dapsone

Abstract

Summary Measurement of glycated haemoglobin (HbA1c) has been utilised in assessing long-term control of blood glucose in patients with diabetes, as well as diagnosing diabetes and identifying patients at increased risk of developing diabetes in the future. HbA1c reflects the level of blood glucose to which the erythrocyte has been exposed during its lifespan, and there are a number of clinical situations affecting the erythrocyte life span in which HbA1c values may be spuriously high or low and therefore not reflective of the true level of glucose control. In the present case series, we describe the particulars of three patients with diabetes who had spuriously low HbA1c levels as a result of dapsone usage. Furthermore, we discuss the limitations of HbA1c testing and the mechanisms by which it may be affected by dapsone in particular. Learning points: Various conditions and medications can result in falsely low HbA1c. Dapsone can lead to falsely low HbA1c by inducing haemolysis and by forming methaemoglobin. Capillary glucose measurement, urine glucose measurements and fructosamine levels should be used as alternatives to HbA1c for monitoring glycaemic control if it was falsely low or high.

Methemoglobinemia in the Era of COVID-19: A Potential Confounder of Glycemic Control

“…In methemoglobinemia, oxidation of the iron atoms in hemoglobin from the ferrous (Fe 2+ ) to ferric (Fe 3+ ) state produces a structural change in hemoglobin that impairs its ability to offload oxygen to tissues and can result in tissue ischemia. The methemoglobin molecule is thought to interfere with the liquid chromatography assay used to measure HbA 1c , producing falsely low values [ 3 ]. Different laboratory techniques used to measure HbA 1c vs fructosamine (in this case, turbidimetric inhibition immunoassay, or TINIA, for HbA 1c , vs colorimetric method for fructosamine) may be affected in different ways by methemoglobinemia, thus explaining the discrepancy in this patient.…”

Trends in Quantification of HbA1c Using Electrochemical and Point-of-Care Analyzers

“…Therefore, initial testing needs to be performed to screen the person for hemoglobinopathies before HbA1c measurements to avoid errors. Similarly, conditions leading to blood loss or hemolytic anemia have also been reported to result in erroneous HbA1c values [ 109 ]. Another facet in diagnosis using HbA1c levels is the variations in the predictions based on HbA1c with those based on blood glucose and glycated albumin levels, which are referred to as the hemoglobin glycation index (HGI) and glycation gap (GG), respectively [ 110 ].…”

HIV and type 2 diabetes: An evolving story

“…This report is misleading, as two of the cases included individuals taking dapsone for pneumocystis carinii pneumonia (PCP). Dapsone is a medication known to cause HbA 1c discrepancy through haemolysis and/or formation of methaemoglobin [93]. Despite this, the report formed the basis for a further study by Diop et al [84].…”